Search research articles
Contact Us
Filters
Showing results (521-530 of 616) with videos related to
Page
of 62
Sort By:
Journal of the American College of Cardiology
|
June 21, 2023
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
Muhammad Shariq Usman, Tariq Jamal Siddiqi, Stefan D Anker, et al.
Lancet (London, England)
|
August 24, 2024
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
John Deanfield, Subodh Verma, Benjamin M Scirica, et al.
Nature Communications
|
December 22, 2011
BRCA1 is an essential regulator of heart function and survival following myocardial infarction
Praphulla C Shukla, Krishna K Singh, Adrian Quan, et al.
Circulation. Heart Failure
|
January 21, 2020
Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure
Nikole J Byrne, Nobutoshi Matsumura, Zaid H Maayah, et al.
The New England Journal of Medicine
|
November 17, 2020
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L Bhatt, Michael Szarek, P Gabriel Steg, et al.
Circulation
|
October 5, 2020
Randomized, Controlled Trial Comparing Mitral Valve Repair With Leaflet Resection Versus Leaflet Preservation on Functional Mitral Stenosis: The CAMRA CardioLink-2 Study
Vincent Chan, C David Mazer, Faeez Mohamad Ali, et al.
Journal of the American College of Cardiology
|
February 14, 2024
Vascular Regenerative Cell Deficiencies in South Asian Adults
Aishwarya Krishnaraj, Ehab Bakbak, Hwee Teoh, et al.
The Journal of Clinical Endocrinology and Metabolism
|
October 1, 2022
Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock
Hang-Long Li, Yi-Kei Tse, Chanchal Chandramouli, et al.
Circulation
|
November 11, 2020
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial
Stefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
European Heart Journal
|
July 14, 2023
Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table
Francesco Cosentino, Subodh Verma, Philip Ambery, et al.
Page
of 62
Search research articles
Search
Showing results (521-530 of 616) with videos related to
Sort By:
Page
of 62
Journal of the American College of Cardiology
|
June 21, 2023
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
Muhammad Shariq Usman, Tariq Jamal Siddiqi, Stefan D Anker, et al.
Lancet (London, England)
|
August 24, 2024
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
John Deanfield, Subodh Verma, Benjamin M Scirica, et al.
Nature Communications
|
December 22, 2011
BRCA1 is an essential regulator of heart function and survival following myocardial infarction
Praphulla C Shukla, Krishna K Singh, Adrian Quan, et al.
Circulation. Heart Failure
|
January 21, 2020
Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure
Nikole J Byrne, Nobutoshi Matsumura, Zaid H Maayah, et al.
The New England Journal of Medicine
|
November 17, 2020
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L Bhatt, Michael Szarek, P Gabriel Steg, et al.
Circulation
|
October 5, 2020
Randomized, Controlled Trial Comparing Mitral Valve Repair With Leaflet Resection Versus Leaflet Preservation on Functional Mitral Stenosis: The CAMRA CardioLink-2 Study
Vincent Chan, C David Mazer, Faeez Mohamad Ali, et al.
Journal of the American College of Cardiology
|
February 14, 2024
Vascular Regenerative Cell Deficiencies in South Asian Adults
Aishwarya Krishnaraj, Ehab Bakbak, Hwee Teoh, et al.
The Journal of Clinical Endocrinology and Metabolism
|
October 1, 2022
Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock
Hang-Long Li, Yi-Kei Tse, Chanchal Chandramouli, et al.
Circulation
|
November 11, 2020
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial
Stefan D Anker, Javed Butler, Gerasimos Filippatos, et al.
European Heart Journal
|
July 14, 2023
Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table
Francesco Cosentino, Subodh Verma, Philip Ambery, et al.
Page
of 62